Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)

Intron-A/Aldara Combination Therapy for BCC Excluding the Face and Scalp

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00581425

Enrollment

Registered

2007-12-27

Start date

2007-12-31

Completion date

2011-09-30

Last updated

2013-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Basal Cell Carcinoma

Keywords

BCC, Basal Cell Carcinoma, Intron-A, Aldara, Basal Cell Carcinoma excluding scalp and face

Brief summary

A trial to see if BCC excluding the scalp and face can be treated successfully with a combination therapy of Intron-A and Aldara.

Interventions

BIOLOGICALImiquimod and Interferon alpha

Imiquimod first two weeks and last two weeks. Interferon middle five weeks.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Nodular or superficial basal cell carcinoma on the skin excluding scalp or face

Exclusion criteria

* Pregnancy

Design outcomes

Primary

Measure	Time frame
resolution of basal cell carcinoma	2 years

Secondary

Measure	Time frame
resolution of basal cell carcinoma at a lower cost and less inflammation.	2 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026